Cadila Healthcare is currently trading at Rs. 433.00, up by 1.95 points or 0.45% from its previous closing of Rs. 431.05 on the BSE.

The scrip opened at Rs. 432.00 and has touched a high and low of Rs. 436.05 and Rs. 428.05 respectively. So far 73023 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 509.35 on 15-Jan-2021 and a 52 week low of Rs. 248.00 on 27-Mar-2020.

Last one week high and low of the scrip stood at Rs. 437.75 and Rs. 408.40 respectively. The current market cap of the company is Rs. 44123.31 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 16.96% and 7.97% respectively.

In a significant move, Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection. Remdac which was launched in August 2020 at Rs. 2800, continues to be India’s most economical brand of Remdesivir and a critical drug in the treatment of COVID-19. This move to further revise the prices will go a long way in helping patients during these critical times.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×